Clarity Medical Group Holding Ltd. has announced the establishment of a special investigation committee in response to certain allegations concerning two of its directors. The company has appointed PricewaterhouseCoopers Consulting Hong Kong Limited as the forensic adviser for the investigation. The allegations include the provision of funding by CEO Jiang Bo to a substantial shareholder for acquiring the company's shares, and the exclusion of certain directors in setting the scope of work for a reply to the Stock Exchange. The committee aims to deliver a preliminary investigation report to the board within eight weeks, although this timeline may be subject to change.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.